in € million* | Q2 2022 | Q1 2022 | Q2 2021 | Q-Q Δ | Y-Y Δ |
Revenues |
59.4
|
41.5
|
38.2
|
43 %
|
55 %
|
Monjuvi product sales |
21.7
|
16.6
|
14.9
|
31 %
|
46 %
|
Royalties |
22.0
|
19.0
|
13.7
|
16 %
|
61 %
|
Licenses, milestones and other |
15.7
|
5.8
|
9.6
|
> 100%
|
64 %
|
* Differences due to rounding. |
in € million* | H1 2022 | H1 2021 | Y-Y Δ |
Revenues |
100.9
|
85.4
|
18 %
|
Monjuvi product sales |
38.3
|
27.8
|
38 %
|
Royalties |
41.0
|
25.4
|
61 %
|
Licenses, milestones and other |
21.5
|
32.3
|
(33) %
|
* Differences due to rounding. |
Amounts in million | Updated 2022 Financial Guidance | Previous* 2022 Financial Guidance | 2022 Guidance Insights |
Monjuvi U.S. Net Product Sales | US$ 90m to 110m | US$ 110m to 135m | 100% of Monjuvi U.S. product sales are recorded on MorphoSys' income statement and related profit/loss is split 50/50 between MorphoSys and Incyte. |
Gross Margin for Monjuvi U.S. Net Product Sales | 75% to 80% | 75% to 80% | 100% of Monjuvi U.S. product cost of sales are recorded on MorphoSys' income statement and related profit/loss is split 50/50 between MorphoSys and Incyte. |
R&D expenses | € 275m to 300m | € 300m to 325m | Reduction in guidance range driven primarily by license agreement for felzartamab to HIBio executed on June 14, 2022. |
SG&A expenses | € 150m to 165m | € 155m to 170m | 53% to 58% of mid-point of SG&A expenses represent Monjuvi U.S. selling costs of which 100% are recorded in MorphoSys' income statement. Incyte reimburses MorphoSys for half of these selling expenses. |
in € million | H1 2022 | H1 2021 | Δ | Q2 2022 | Q2 2021 | Δ | ||
Revenues |
100.9
|
85.4
|
18 %
|
59.4
|
38.2
|
55 %
| ||
Product Sales |
38.3
|
27.8
|
38 %
|
21.7
|
14.9
|
46 %
| ||
Royalties |
41.0
|
25.4
|
61 %
|
22.0
|
13.7
|
61 %
| ||
Licenses, milestones and other |
21.5
|
32.3
|
(33) %
|
15.7
|
9.6
|
64 %
| ||
Cost of Sales |
(25.1)
|
(15.2)
|
65 %
|
(17.2)
|
(10.1)
|
70 %
| ||
Gross Profit |
75.8
|
70.2
|
8 %
|
42.2
|
28.1
|
50 %
| ||
Total Operating Expenses |
(198.8)
|
(171.2)
|
16 %
|
(97.3)
|
(99.5)
|
(2) %
| ||
Research and Development |
(126.0)
|
(73.8)
|
71 %
|
(60.9)
|
(40.5)
|
50 %
| ||
Selling |
(45.9)
|
(56.6)
|
(19) %
|
(24.0)
|
(28.5)
|
(16) %
| ||
General and Administrative |
(27.0)
|
(40.8)
|
(34) %
|
(12.4)
|
(30.5)
|
(59) %
| ||
Operating Profit / (Loss) |
(123.1)
|
(101.0)
|
22 %
|
(55.1)
|
(71.4)
|
(23) %
| ||
Other Income |
9.2
|
2.8
|
>100%
|
7.8
|
1.7
|
>100%
| ||
Other Expenses |
(15.5)
|
(3.4)
|
>100%
|
(11.8)
|
(1.4)
|
>100%
| ||
Finance Income |
16.7
|
116.3
|
(86) %
|
6.2
|
102.4
|
(94) %
| ||
Finance Expenses |
(248.0)
|
(36.8)
|
>100%
|
(185.1)
|
2.9
|
>(100)%
| ||
Income from Reversals of Impairment Losses / (Impairment Losses) on Financial Assets |
(1.0)
|
0.3
|
>(100)%
|
(1.0)
|
0.2
|
>(100)%
| ||
Income Tax Benefit / (Expenses) |
4.0
|
1.0
|
>100%
|
4.0
|
(13.5)
|
>(100)%
| ||
Consolidated Net Profit / (Loss) |
(357.6)
|
(20.7)
|
>100%
|
(235.0)
|
20.9
|
>(100)%
| ||
Earnings per Share, Basic and Diluted |
(10.47)
|
(0.63)
|
>100%
|
(6.88)
|
-
|
-
| ||
Earnings per Share, Basic |
-
|
-
|
-
|
-
|
0.64
|
-
| ||
Earnings per Share, Diluted |
-
|
-
|
-
|
-
|
0.61
|
-
| ||
Cash and other financial assets (end of period) |
754.3
|
976.9 *
|
(23) %
|
754.3
|
976.9 *
|
(23) %
|
Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 899 27 26079
thomas.biegi@morphosys.com
|
Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
|
Kaitlyn Nealy
Senior Director
Tel: +1 857 321 8449
kaitlyn.nealy@morphosys.com
|
Myles Clouston
Senior Director
Tel: +1 857 772 0240
myles.clouston@morphosys.com
|
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
MorphoSys AG published this content on 04 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 13:17:11 UTC.